Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Radioiodine-Associated Exacerbation of Graves’ Orbitopathy in the Japanese Population: Randomized Prospective Study
source: The Journal of Clinical Endocrinology and Metabolism
year: 2015
authors: Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto M, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K
summary/abstract:Context:
Exacerbation of Graves’ orbitopathy (GO) after radioiodine (RAI) therapy has been examined in some populations but has not been fully described in Japanese populations.
Objective:
The purpose of this study was to clarify the characteristics of GO exacerbation after RAI therapy and the effectiveness of low-dose prophylactic corticosteroid (PCS).
Design and Setting:
This was a prospective randomized study in Tokyo, Japan.
Patients:
Between June 2011 and June 2012, 295 patients with Graves’ disease with either inactive GO or no GO received RAI therapy. Of these, 147 received no PCS (PCS-Off group), whereas 148 received low-dose PCS (starting dose, 15 mg/day of prednisolone) for 6 weeks (PCS-On group). We used magnetic resonance imaging to thoroughly evaluate GO before and 1 year after RAI therapy.
Main Outcome Measures:
Outcomes of GO 1 year after RAI therapy were determined.
Results:
GO exacerbation occurred in 29 patients (9.8%), and only 7 patients (2.4%) required ophthalmic treatment. No significant difference in the frequency of GO exacerbation was seen between the groups (PCS-On group: n = 18 [12.1%]; PCS-Off group: n = 11 [7.5%]; P = .17). Significant prognostic factors were identified as thyroid-stimulating antibody (by 100% linear increase: risk ratio, 1.15; 95% confidence interval, 1.07-1.24; P = .0003) and clinical activity score (≥1 vs 0: risk ratio, 6.40; 95% confidence interval, 2.17-19.7; P = .0009).
Conclusion:
Exacerbation of GO after RAI therapy in the Japanese population appears less common than in other populations. Low-dose PCS did not produce a significant preventive effect and appeared insufficient. Patients presenting with risk factors would thus be recommended to receive higher-dose PCS.
DOI: 10.1210/jc.2014-4542
read more full text
myBinderRelated Content
-
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ OphthalmopathyThe purpose of the current study is to c...
-
The Medical University of South Carolina Health Graves’ Eye Disease ClinicThe Medical University of South Carolina...
-
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
-
How to Identify Thyroid Eye Disease (TED)https://www.youtube.com/watch?v=OTVeFLCu...
-
Clinical Outcomes of Graves’ Ophthalmopathy Treated with Intensity Modulated Radiation TherapyBackground: Radiation for Graves’ oph...
-
Immunotherapy for Graves’ OphthalmopathyPurpose of Review: In recent years, imm...
-
Treatment Options for Thyroid Eye or Graves’ Disease at Ohio Statehttps://www.youtube.com/watch?v=2vcbs9hu...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google